153 related articles for article (PubMed ID: 12604217)
1. Hydrogen bonding interactions between aldose reductase complexed with NADP(H) and inhibitor tolrestat studied by molecular dynamics simulations and binding assay.
Lee YS; Hodoscek M; Kador PF; Sugiyama K
Chem Biol Interact; 2003 Feb; 143-144():307-16. PubMed ID: 12604217
[TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics simulations of the structure of aldose reductase complexed with the inhibitor tolrestat.
Rastelli G; Costantino L
Bioorg Med Chem Lett; 1998 Mar; 8(6):641-6. PubMed ID: 9871575
[TBL] [Abstract][Full Text] [Related]
3. Isolation of a non-covalent aldose reductase-nucleotide-inhibitor complex.
Sugiyama K; Chen Z; Lee YS; Kador PF
Biochem Pharmacol; 2000 Feb; 59(4):329-36. PubMed ID: 10644040
[TBL] [Abstract][Full Text] [Related]
4. Studies on the inhibitor-binding site of porcine aldehyde reductase: crystal structure of the holoenzyme-inhibitor ternary complex.
el-Kabbani O; Carper DA; McGowan MH; Devedjiev Y; Rees-Milton KJ; Flynn TG
Proteins; 1997 Oct; 29(2):186-92. PubMed ID: 9329083
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of human aldehyde reductase: characterization of the active site pocket.
Barski OA; Gabbay KH; Grimshaw CE; Bohren KM
Biochemistry; 1995 Sep; 34(35):11264-75. PubMed ID: 7669785
[TBL] [Abstract][Full Text] [Related]
6. Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase.
Carbone V; Zhao HT; Chung R; Endo S; Hara A; El-Kabbani O
Bioorg Med Chem; 2009 Feb; 17(3):1244-50. PubMed ID: 19121944
[TBL] [Abstract][Full Text] [Related]
7. The crystallographic structure of the aldose reductase-IDD552 complex shows direct proton donation from tyrosine 48.
Ruiz F; Hazemann I; Mitschler A; Joachimiak A; Schneider T; Karplus M; Podjarny A
Acta Crystallogr D Biol Crystallogr; 2004 Aug; 60(Pt 8):1347-54. PubMed ID: 15272156
[TBL] [Abstract][Full Text] [Related]
8. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil.
Urzhumtsev A; Tête-Favier F; Mitschler A; Barbanton J; Barth P; Urzhumtseva L; Biellmann JF; Podjarny A; Moras D
Structure; 1997 May; 5(5):601-12. PubMed ID: 9195881
[TBL] [Abstract][Full Text] [Related]
9. Docking and molecular dynamics study on the inhibitory activity of coumarins on aldose reductase.
Wang Z; Ling B; Zhang R; Liu Y
J Phys Chem B; 2008 Aug; 112(32):10033-40. PubMed ID: 18637681
[TBL] [Abstract][Full Text] [Related]
10. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations.
Sotriffer CA; Krämer O; Klebe G
Proteins; 2004 Jul; 56(1):52-66. PubMed ID: 15162486
[TBL] [Abstract][Full Text] [Related]
11. High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group.
Steuber H; Zentgraf M; Podjarny A; Heine A; Klebe G
J Mol Biol; 2006 Feb; 356(1):45-56. PubMed ID: 16337231
[TBL] [Abstract][Full Text] [Related]
12. Human aldose reductase: pK of tyrosine 48 reveals the preferred ionization state for catalysis and inhibition.
Grimshaw CE; Bohren KM; Lai CJ; Gabbay KH
Biochemistry; 1995 Nov; 34(44):14374-84. PubMed ID: 7578041
[TBL] [Abstract][Full Text] [Related]
13. Induced fit docking, pharmacophore modeling, and molecular dynamic simulations on thiazolidinedione derivatives to explore key interactions with Tyr48 in polyol pathway.
Vijjulatha M; Lingala Y; Merugu RT
J Mol Model; 2014 Jul; 20(7):2348. PubMed ID: 24974084
[TBL] [Abstract][Full Text] [Related]
14. Nitrophenyl derivatives as aldose reductase inhibitors.
Costantino L; Ferrari AM; Gamberini MC; Rastelli G
Bioorg Med Chem; 2002 Dec; 10(12):3923-31. PubMed ID: 12413844
[TBL] [Abstract][Full Text] [Related]
15. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
Ruiz FX; Cousido-Siah A; Mitschler A; Farrés J; Parés X; Podjarny A
Chem Biol Interact; 2013 Feb; 202(1-3):178-85. PubMed ID: 23295227
[TBL] [Abstract][Full Text] [Related]
16. Docking and molecular dynamics studies toward the binding of new natural phenolic marine inhibitors and aldose reductase.
Wang Z; Ling B; Zhang R; Suo Y; Liu Y; Yu Z; Liu C
J Mol Graph Model; 2009 Sep; 28(2):162-9. PubMed ID: 19616461
[TBL] [Abstract][Full Text] [Related]
17. Rotamers of tolrestat and their binding mode to aldose reductase.
Lee YS; Sugiyama K; Kador PF
Adv Exp Med Biol; 1999; 463():465-72. PubMed ID: 10352720
[No Abstract] [Full Text] [Related]
18. Novel insights into the structural requirements for the design of selective and specific aldose reductase inhibitors.
Kumar H; Shah A; Sobhia ME
J Mol Model; 2012 May; 18(5):1791-9. PubMed ID: 21833829
[TBL] [Abstract][Full Text] [Related]
19. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors.
El-Kabbani O; Darmanin C; Schneider TR; Hazemann I; Ruiz F; Oka M; Joachimiak A; Schulze-Briese C; Tomizaki T; Mitschler A; Podjarny A
Proteins; 2004 Jun; 55(4):805-13. PubMed ID: 15146479
[TBL] [Abstract][Full Text] [Related]
20. In vitro studies of potent aldose reductase inhibitors: Synthesis, characterization, biological evaluation and docking analysis of rhodanine-3-hippuric acid derivatives.
Celestina SK; Sundaram K; Ravi S
Bioorg Chem; 2020 Apr; 97():103640. PubMed ID: 32086051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
